DrugPatentWatch Database Preview

Details for Patent: 6,858,650

« Back to Dashboard

Which drugs does patent 6,858,650 protect, and when does it expire?

Patent 6,858,650 protects TOVIAZ and is included in one NDA.

This patent has seventy-eight patent family members in twenty-nine countries.

Summary for Patent: 6,858,650

Title:	Stable salts of novel derivatives of 3,3-diphenylpropylamines
Abstract:	The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for the manufacture and highly pure, stable intermediate products. The method is in particular characterized by regio- and chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-diphenylpropylamines are provided, that are particularly well-suited for use in pharmaceutical formulations. Preferred compounds are R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenylisobutyr ate ester hydrogen fumarate and R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyra te ester hydrochloride hydrate. Furthermore, stable, crystalline intermediate products that are essential for obtaining the abovementioned salts are provided. A preferred intermediate product is R-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester.
Inventor(s):	Meese; Claus (Monheim, DE)
Assignee:	Schwarz Pharma AG (DE)
Application Number:	10/130,214
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,858,650
Patent Claim Types: see list of patent claims	Compound; Formulation; Use;

Drugs Protected by US Patent 6,858,650

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-001	Oct 31, 2008	AB	RX	Yes	No				Y		TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-002	Oct 31, 2008	AB	RX	Yes	Yes				Y		TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY

Foreign Priority and PCT Information for Patent: 6,858,650

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	199 55 190	Nov 16, 1999

PCT Information
PCT Filed	November 15, 2000	PCT Application Number:	PCT/EP00/11309
PCT Publication Date:	May 25, 2001	PCT Publication Number:	WO01/35957

International Family Members for US Patent 6,858,650

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	286872
Austria	337293
Austria	395056